[go: up one dir, main page]

ID16781A - PHARMACEUTICAL FORMULATIONS - Google Patents

PHARMACEUTICAL FORMULATIONS

Info

Publication number
ID16781A
ID16781A IDP970927A ID970927A ID16781A ID 16781 A ID16781 A ID 16781A ID P970927 A IDP970927 A ID P970927A ID 970927 A ID970927 A ID 970927A ID 16781 A ID16781 A ID 16781A
Authority
ID
Indonesia
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Application number
IDP970927A
Other languages
Indonesian (id)
Inventor
Arup K Roy
Lioyd Gary Tillman
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606372.2A external-priority patent/GB9606372D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ID16781A publication Critical patent/ID16781A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IDP970927A 1996-03-22 1997-03-21 PHARMACEUTICAL FORMULATIONS ID16781A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1389396P 1996-03-22 1996-03-22
GBGB9606372.2A GB9606372D0 (en) 1996-03-26 1996-03-26 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ID16781A true ID16781A (en) 1997-11-13

Family

ID=26308992

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP970927A ID16781A (en) 1996-03-22 1997-03-21 PHARMACEUTICAL FORMULATIONS

Country Status (12)

Country Link
JP (1) JP3117726B2 (en)
AR (1) AR006345A1 (en)
BG (1) BG64457B1 (en)
CO (1) CO4790151A1 (en)
HU (1) HU228026B1 (en)
ID (1) ID16781A (en)
IL (1) IL126185A (en)
MY (1) MY126358A (en)
OA (1) OA10880A (en)
PL (1) PL187919B1 (en)
TW (1) TW455491B (en)
WO (1) WO1997035587A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264718C (en) * 1996-09-01 2006-05-30 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
AU8145198A (en) * 1997-06-16 1999-01-04 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
ES2140329B1 (en) * 1997-12-04 2000-10-16 Univ Granada USE OF MASLINIC ACID AS A PROTEASE INHIBITOR FOR THE TREATMENT OF DISEASE CAUSED BY THE VIRUSES OF ACQUIRED IMMUNODEFICIENCY.
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
CA2432527A1 (en) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
WO2004050068A1 (en) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EP1592760A4 (en) 2003-01-31 2009-08-12 Smithkline Beecham Corp Solid dispersion compositions
EP1799194B1 (en) * 2004-09-24 2011-11-16 Boehringer Ingelheim Pharmaceuticals Inc. A new class of surfactant-like materials comprising vitamin e tpgs and a water soluble polymer
EP1793806A2 (en) * 2004-09-30 2007-06-13 Eastman Chemical Company Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
SA109300195B1 (en) 2008-03-28 2013-04-20 Astrazeneca Ab A Novel Anti-Cancer Pharmaceutical Composition
ITRM20120331A1 (en) 2012-07-12 2014-01-13 Guidotti & C Spa Labor LIQUID ORAL PEDIATRIC COMPOSITIONS CONTAINING NEPADUTANT.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016501A1 (en) * 1991-03-20 1992-10-01 Vertex Pharmaceuticals Incorporated Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease
NZ244986A (en) * 1991-11-08 1995-10-26 Merck & Co Inc Hiv protease inhibitor and pharmaceutical compositions
IS2334B (en) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl protease inhibitor of a new class of sulfonamides
WO1994013629A1 (en) * 1992-12-11 1994-06-23 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
DE10199053I1 (en) * 1992-12-29 2002-08-29 Abbott Lab Retroviral protease inhibitors
ATE179164T1 (en) * 1993-01-15 1999-05-15 Agouron Pharma HIV PROTEASE INHIBITORS
WO1995012583A1 (en) * 1993-11-05 1995-05-11 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
IL111584A0 (en) * 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
HUT74681A (en) * 1993-12-15 1997-01-28 Merck & Co Inc N-(2-hydroxy-1-indenyl)-2-phenylmethyl-4-hydroxy-5-(2-carboxamido-piperazinyl)-pentaneamide derivatives of hiv protease inhibitor activity and phrmaceutical compositions contining them
WO1995024385A1 (en) * 1994-03-07 1995-09-14 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0825849A1 (en) * 1995-05-19 1998-03-04 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs

Also Published As

Publication number Publication date
BG102838A (en) 1999-09-30
JP3117726B2 (en) 2000-12-18
IL126185A0 (en) 1999-05-09
MY126358A (en) 2006-09-29
IL126185A (en) 2003-05-29
TW455491B (en) 2001-09-21
PL187919B1 (en) 2004-11-30
PL328916A1 (en) 1999-03-01
OA10880A (en) 2001-10-11
WO1997035587A1 (en) 1997-10-02
HUP9901887A2 (en) 1999-12-28
AR006345A1 (en) 1999-08-25
BG64457B1 (en) 2005-03-31
JP2000500504A (en) 2000-01-18
HU228026B1 (en) 2012-08-28
HUP9901887A3 (en) 2000-02-28
CO4790151A1 (en) 1999-05-31

Similar Documents

Publication Publication Date Title
BR9610153A (en) Pharmaceutical formulations
BR9611626A (en) Pharmaceutical formulations
ID23299A (en) PHARMACEUTICAL FORMULATIONS
ID24654A (en) OMEPRAZOLA PHARMACEUTICAL FORMULATION
ID18352A (en) PHARMACEUTICAL COMPOSITIONS
DE69530325D1 (en) AEROSOL DRUG FORMULATIONS
MA24473A1 (en) FORMULATIONS
FI20071025L (en) Pharmaceutical compositions
NO954486D0 (en) Pharmaceutical formulation basis
FI991302L (en) Improved pharmaceutical compositions
ID16781A (en) PHARMACEUTICAL FORMULATIONS
TR199501082A2 (en) Pharmaceutical formulations.
ID29294A (en) PHARMACEUTICAL COMPOSITION
ITMI941169A0 (en) PHARMACEUTICAL FORMULATIONS
PT941100E (en) PHARMACEUTICAL COMPOSITIONS
EE03511B1 (en) Prolonged release pharmaceutical preparations containing misolastin
ID25857A (en) PHARMACEUTICAL COMPOSITION
FI951155A7 (en) Pharmaceutical preparation
FI961364L (en) Drug composition
ITMI962628A0 (en) PHARMACEUTICAL COMPOSITION
NO991430L (en) Insecticide formulations
FI954050L (en) Pharmaceutical compositions
ID23531A (en) PHARMACEUTICAL COMPOSITION
SE9600141D0 (en) Pharmaceutical formulation
SE9404467D0 (en) Drug formulations